Summary. HB 699 is a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. The mechanisms whereby it affects B-cell function have been studied in vitro with mouse islets. In the presence of 3 mmol/1 glucose, HB 699 decreased 86Rb+ efflux and accelerated 45Ca2+ efflux from islet cells, depolarized the B-cell membrane and induced an electrical activity similar to that triggered by stimulatory concentrations of glucose, and increased insulin release. The changes in 45Ca 2+ efflux and insulin release, but not the inhibition of 86Rb+ efflux, were abolished in the absence of Ca 2+. In the presence of 10mmol/1 glucose, HB699 increased 86Rb+ and 4SCa2+ efflux from the islets, caused a persistent depolarization of the B-cell membrane with continuous electrical activity, and markedly potentiated insulin release. All these changes were suppressed by omission of extracellular Ca 2+. In the presence of 15 mmol/1 glucose, diazoxide increased 86Rb+ efflux, hyperpolarized the B-cell membrane, suppressed electrical activity and inhibited insulin release. HB 699 reversed these effects of diazoxide. It is suggested that HB 699 decreases K + permeability of the B-cell membrane, thereby causing a depolarization which leads to activation of voltage-dependent Ca channnels and Ca 2+ influx, and eventually increases insulin release. A sulphonylurea group is thus not a prerequisite to trigger the sequence of events that is also thought to underlie the releasing effects of tolbutamide and glibenclamide.
Summary. HB 699 is a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. The mechanisms whereby it affects B-cell function have been studied in vitro with mouse islets. In the presence of 3 mmol/1 glucose, HB 699 decreased 86Rb+ efflux and accelerated 45Ca2+ efflux from islet cells, depolarized the B-cell membrane and induced an electrical activity similar to that triggered by stimulatory concentrations of glucose, and increased insulin release. The changes in 45Ca 2+ efflux and insulin release, but not the inhibition of 86Rb+ efflux, were abolished in the absence of Ca 2+. In the presence of 10mmol/1 glucose, HB699 increased 86Rb+ and 4SCa2+ efflux from the islets, caused a persistent depolarization of the B-cell membrane with continuous electrical activity, and markedly potentiated insulin release. All these changes were suppressed by omission of extracellular Ca 2+. In the presence of 15 mmol/1 glucose, diazoxide increased 86Rb+ efflux, hyperpolarized the B-cell membrane, suppressed electrical activity and inhibited insulin release. HB 699 reversed these effects of diazoxide. It is suggested that HB 699 decreases K + permeability of the B-cell membrane, thereby causing a depolarization which leads to activation of voltage-dependent Ca channnels and Ca 2+ influx, and eventually increases insulin release. A sulphonylurea group is thus not a prerequisite to trigger the sequence of events that is also thought to underlie the releasing effects of tolbutamide and glibenclamide.
Keywords: Insulin release, ionic fluxes, membrane potential, isolated islets, B-cells, sulphonylureas, benzoic acid derivative.
It has been known for 25 years that hypoglycaemic sulphonamides stimulate insulin release, but the mechanisms by which they affect B-cell function are only partially elucidated [1] . The most effective compounds contain a sulphonylurea group, that was long regarded as an essential structural requirement for the insulin-releasing action. However, it has been reported a few years ago [2] that compound HB 699 or (4-[2-(5-chloro-2 methoxybenzamide)-ethyl]-benzoic acid), which is similar to the non-sulphonylurea moiety of glibenclamide (Fig. I) , also possesses hypoglycaemic properties. This hypoglycaemic action is due to a stimulation of insulin release, that was demonstrated in vivo [2, 3] , and in vitro [2, [4] [5] [6] . The cellular mechanisms of this stimulation are not known and may conceivably be quite different from those of the parent molecule glibenclamide. In vivo studies of various hypoglycaemic compounds have indeed led to the speculation that HB 699 and sulphonylureas interact with the same site [7] or with two different sites [8] on B cells. Recent in vitro experiments were also suggestive of different modes of action [9] .
In this study we have thus measured the effects of HB 699 on 86Rb+ or 45Ca2+ efflux, and on insulin release from mouse islets, as well as on the membrane potential of mouse B cells. These effects have also been compared to those of glibenclamide.
Materials and methods
All experiments were performed with islets of fed female NMRI mice (25-30g), killed by decapitation. For electrophysiological experiments, a piece of pancreas was fixed in a small perifusion chamber, and the membrane potential of single B cells was continuously reCl (~CO-NH-C H2-C H2~-SO2-NH-CO-NH-~
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Gl i bencl ami de corded with microelectrodes [10] . B cells were identified by the typical electrical activity that they display in the presence of 10-15 mmol/1 glucose [11] . For all other experiments, islets were isolated after collagenase digestion of the pancreas. Details of the method used to monitor the efflux of S6Rb+ (used as tracer for K +) or 45Ca 2+ from preloaded islets have been reported elsewhere [12] . During the experiments of 86Rb+ efflux, a portion of each effluent fraction was drawn for measurement of immunoreactive insulin, with rat insulin as standard [13] . The perifusion medium used was a bicarbonate-buffered solution, pH 7.4 [14] , that was supplemented with bovine serum albumin (1 mg/ ml), except for electrophysiological recordings. In certain experiments, CaCI2 was omitted and replaced by MgC12; its total concentration was less than 20 p, mol/1. 
Results

Effects of liB 699 in the presence of a non-stimulatory concentration of glucose
Addition of 10 or 50 ~mol/1 HB 699 to a medium containing 3 mmol/1 glucose and 2.5 mmol/1 Ca 2+ caused an acceleration of 45Ca2+ effiux, an inhibition of 86Rb+ effiux and a stimulation of insulin release from perifused islets (Fig. 2A) . The changes in 45Ca2+ effiux and insulin release were dose-dependent, whereas the decrease in 86Rb+ effiux was more marked with 10 than with 50 ~tmol/1 HB 699. If the medium did not contain Ca 2+, HB 699 did not affect 45Ca2+ efflux or insulin release, but still decreased 86Rb + efflux (Fig. 2 B) . This inhibitory effect reached a steady value sooner than in the presence of Ca 2+ and was similar with both concentrations of the drug. All effects of HB 699 were reversible upon removal of the drug. In the absence of glucose, 50 s HB 699 rapidly decreased 86Rb+ efflux and increased 4~Ca~+ effiux and insulin release with a slight delay. At the concentration of 10 gmol/1, HB 699 also decreased 86Rb+ efflux, but did not consistently affect 45Ca2+ efflux and insulin release (not shown).
When the islets were perifused with a glucose-free medium containing 2.5 mmol/1 Ca 2+, 10 p~mol/1 HB 699 slowly depolarized the B-cell membrane and induced electrical activity (Fig. 3 A) . This activity consisted of slow waves of the membrane potential with spikes superimposed on the plateau. A lower concentration of HB 699 (3 ~mol/1) consistently depolarized the B-cell membrane, but induced electrical activity only transiently in 2 cells out of 4 (not shown). A higher concentration of HB 699 (15 ~tmol/1) caused a more rapid and persistent depolarization of the B-cell membrane, with a continuous spike activity (Fig. 3 B) . Removal of HB 699 was followed by disappearance of the electrical activity and repolarization of the membrane. At a concentration of 3 mmol/1, glucose alone did not affect the membrane potential of B-cells, but amplified the effects of HB 699 (Fig.3C) .
Glibenclamide (0.1 ~tmol/1) accelerated 45Ca2+ elflux, inhibited 86Rb+ efflux and increased insulin release from islets perifused with a medium containing 3 mmol/1 glucose (Fig.2C ). These effects of glibenclamide were slower than those of HB 699 and were not readily reversible by removal of the drug. Under these conditions, glibenclamide slowly depolarized the B-cell membrane and induced a continuous spike activity (not shown). Omission of Ca 2+ abolished the changes in 45Ca2+ efflux and insulin release otherwise brought about by glibenclamide, but amplified its inhibitory effect on 86Rb+ efflux (not shown).
Effects of liB 699 in the presence of a stimulatory concentration of glucose
When the perifusion medium contained 10 mmol/l glucose and 2.5 mmol/1 Ca 2+, the rates of 45Ca2+ efflux and of insulin release were higher, whereas the rate of 86Rb+ efflux was lower than in the presence of 3 mmol/1 glucose. Addition of 2 or 10 Ixmol/1 HB 699 caused a dose-dependent, reversible increase in 45Ca 2+ efflux, 86Rb+ efflux and insulin release from the islets (Fig. 4A ). All these changes were abolished in the absence of Ca 2 + (Fig. 4 B) .
The electrical activity induced by 10 mmol/1 glucose in B-cells was rapidly, markedly and reversibly modified by 3 gmol/1 HB 699. In certain cells, the drug increased the duration of the slow waves with spike activity, and decreased both the duration and the amplitude of the polarized intervals (Fig.5A) . In other cells, HB 699 persistently depolarized the membrane to the plateau level and induced a continuous spike activity (Fig.5 B) .
Glibenclamide (0.02gmol/1) accelerated 45Ca 2+ and 86Rb + efflux, and increased insulin release from islets perifused with a medium containing 10 mmol/1 glucose (Fig.4C) . These effects of glibenclamide were slower than those of HB 699 and were not reversible upon removal of the drug. Under similar conditions, glibenclamide persistently depolarized the B-cell membrane to the plateau level and induced a continuous spike activity (not shown). In the absence of extracellu-lar Ca 2+, the changes in ionic fluxes and insulin release otherwise brought about by glibenclamide were abolished (not shown).
Antagonistic effects of liB 699 and diazoxide
In islets perifused with a medium containing 15 mmol/1 glucose, 100 p.mol/1 diazoxide caused a simultaneous increase in 86Rb+ efflux and inhibition of insulin release. Addition of 5 p~mol/1 HB 699 to the medium containing diazoxide reversed these changes in a reversible manner (Fig. 6) .
Glucose-induced electrical activity rapidly stopped upon addition of diazoxide, and the B-cell membrane markedly hyperpolarized (Fig. 7) . Subsequent introduction of HB 699 reversed these effects in a dose-dependent manner. The restoration of the electrical activity was only partial with 5 gmol/1 HB 699. On the other hand 20 Ixmol/1 HB 699 depolarized the B-cell membrane to the plateau level and induced continuous spike activity, despite the presence of diazoxide. Withdrawal of HB 699 was followed by repolarization of the B-cell membrane (Fig. 7 C) .
Discussion
This study shows that the stimulation of insulin release by HB 699, a benzoic acid derivative corresponding to the non-sulphonylurea moiety of glibenclamide, is accompanied by changes in 45Ca2+ efflux, 86Rb+ effiux and B-cell membrane potential qualitatively similar to those induced by tolbutamide [15] [16] [17] [18] or by glibenclamide itself. A precise estimation of their relative potencies was not the purpose of the study. However, comparison of the present data with published [15] [16] [17] [18] [19] [20] and unpublished results (J. C.H. and H.P.M.) shows that, on all parameters measured here, HB699 is slightly more potent (2-5 X) than tolbutamide, but much less potent (100-200 X) than glibenclamide. Also by the rapidity of onset and reversibility of its effects HB 699 resembles tolbutamide more than glibenclamide, all effects of which are slower and not readily reversible upon washing [21] [22] [23] . Finally, it should be pointed out that the concentration of free HB 699 is likely to be higher in electrophysiological experiments which are carried out in the absence of albumin than in other experiments. Comparison of the effects of a given concentration of the drug on membrane potential and on other aspects of the B-cell function should thus be made with this reservation in mind. In particular, this may explain why, in the absence of glucose, 10 p.mol/l HB 699 depolarized the B-cell membrane (and decreased 86Rb+ efflux), but failed to stimulate 45Ca2+ efflux and insulin release.
There is now general agreement that an increase of Ca 2+ influx in B cells is an essential step in the stimulation of insulin release by sulphonylureas. This consensus is based on measurements of both 45Ca2+ fluxes in islet cells [15, 17, [24] [25] [26] and membrane potential in B cells [16, 18, 19, 22, 27] . The possible role of Ca 2+ in the B-cell response to HB 699 has been addressed in three studies, but the results are conflicting. From measurements of 45Ca2+ uptake by ob/ob mouse islets, it was concluded that the effects of HB 699 on the Ca 2+ permeability of the B-cell membrane are not the same as those of glibenclamide or tolbutamide [28] . It was proposed that a mobilization of cellular Ca 2+ contributes to the releasing action of HB 699. Such a view is compatible with the report that omission of extracellular Ca 2+ inhibited HB699-induced insulin release only partially in incubated rat islets [6] . On the other hand, the stimulation of release and the increase in 45Ca 2+ content of rat islets brought about by a very high concentration of HB 699 (1.2 mmol/1) were found to be inhibited by verapamil, a blocker of voltage-dependent Ca-channels [29] .
In the present study, the stimulatory effect of HB 699 (and of glibenclamide) on insulin release and 45Ca2+ efflux displayed similar time-course and dosedependency. Both changes were abolished by omission of extracellular Ca 2+. Analogous observations have been made with tolbutamide [17] and gliclazide [26] , and interpreted as evidence for a stimulation of Ca 2+ influx (with secondary displacement of radioactive cellular 45Ca2+), without any substantial direct effect of the drugs on intracellular Ca 2+ stores. The appearance or the increase of an electrical activity underlain by Ca 2+ inward currents [30] also fully supports the contention that HB 699 increases insulin release by stimulating Ca 2+ influx in B cells.
The membrane potential of non-stimulated B cells is mainly determined by the high relative K + permeability of the plasma membrane [31] . Qualitative changes of this latter can be established by measuring 86Rb + effiux from islet cells in parallel with the membrane potential [30] . The observations that HB 699 simultaneously decreased 86Rb+ efflux and depolarized the B-cell membrane strongly suggest that the drug decreases K + permeability of the B-cell membrane and that this decrease is the cause of the depolarization. A similar mechanism is believed to cause the depolarization produced by tolbutamide or glibenclamide [15, 16, 18, 19, 32] .
Unlike the changes in 45Ca2+ efflux or insulin release, the changes in 86Rb+ efflux induced by HB 699 were not always dose-dependent. In a medium containing 3 mmol/1 glucose, the inhibition of effiux was more marked with 10 than with 50 p.mol/1 HB 699, whereas the rebound following removal of the drug was more concentration-dependent. Moreover, this peculiarity, which also characterizes the effect of tolbutamide [18, 32] , was only observed in the presence of Ca 2+. It can be ascribed to the activation of K channels by the greater influx of Ca 2+ [12] and more sustained depolarization of the B-cell membrane in the presence of the highest concentrations of HB 699 or tolbutamide.
It is currently admitted that the repolarization phase of the slow waves of membrane potential induced by glucose in B cells is, at least partially, due to an increase in K + permeability [30] . The lengthening of these slow waves and the decrease in duration and amplitude of the polarized intervals in certain cells, as well as the sustained depolarization at the plateau level in other cells, suggest that HB 699 also reduces K + permeability of the B-cell membrane in the presence of a stimulatory concentration of glucose. Such a conclusion may seem in contradiction with the acceleration of 86Rb + efflux produced by the drug under these conditions. However, similar changes occur upon addition of tolbutamide [15, 18, 33] or leucine [34, 35] to a medium containing a stimulatory concentration of glucose, although the genuine effect of these substances is to decrease the K § permeability of the B-cell membrane. This paradoxical increase in 86Rb+ efflux, which did not occur in the absence of Ca 2+ and which was paralleled by the stimulation of 45Ca2+ efflux by HB 699, can be explained by the activation of K-channels by the incoming Ca 2+ [12] , and by the more sustained depolarization of the membrane.
We have previously demonstrated that the inhibition of insulin release by diazoxide is due to the ability of this sulphonamide to hyperpolarize the B-cell membrane by increasing its permeability to K + [18] . The present study confirms this mechanism of action and further shows that HB 699 is able to reverse the effects of diazoxide on 86Rb + efflux, B-cell membrane potential and insulin release. This property, shared with tolbutamide, tetraethylammonium, quinine and sparteine [18, 36] lends further support to the proposal that HB 699 affects B-cell function by decreasing the K + permeability of the plasma membrane.
In conclusion, the following sequence of events, can be proposed for the stimulation of insulin release by HB 699. The drug decreases K + permeability of the Bcell membrane and, thereby, causes depolarization. This activates voltage-dependent Ca-channels and permits Ca 2+ influx. The same sequence has been proposed to explain the releasing action of tolbutamide and glibenclamide [15, 16, 18, 19, 32] . This underlines the crucial importance of K-channels of B cells as targets for pharmacological insulinotropic agents, and demonstrates that a sulphonylurea group is not a prerequisite for the interaction with these channels.Further studies will help to elucidate the molecular requirements for such interaction and, hopefully, open new perspectives for designing insulinotropic drugs.
